RTS,S/AS01 (Mosquirix) Malaria Vaccine Rollout
Malaria prevention in children in sub-Saharan Africa
Sponsor: GSK
- N/AEnrollment target
- 25Trial sites
- 5Countries
- TBDEst. completion
- N/ARegistry record
About this trial
GSK's RTS,S/AS01 was the first malaria vaccine recommended by the WHO, in October 2021, and is now in routine immunisation schedules across sub-Saharan Africa. R21/Matrix-M, which this row previously credited to GSK, is an Oxford, Novavax and Serum Institute of India vaccine.
Primary endpoints
- All-cause child mortality
- Severe malaria incidence
Latest update
A four-country Lancet evaluation reported that RTS,S/AS01E averted about one in eight deaths among eligible children in Ghana, Kenya and Malawi over four years, cutting all-cause child mortality by 13.2 per cent and severe malaria by 21.6 per cent. Fourth-dose coverage of just 39.9 per cent highlighted a booster-completion gap as malaria vaccines reached routine schedules in 25 sub-Saharan African countries.
SourceTrial information is compiled from public sources and may be out of date. It is not medical advice and is not an offer of enrolment; check the registry entry or speak to a physician before acting on it.